Skip to main content
. 2018 Oct 19;19(10):3234. doi: 10.3390/ijms19103234

Figure 1.

Figure 1

Effect of combination treatment with sorafenib (SOR) and betulinic acid (BA) on cell growth inhibition of PDAC cell lines. (A) Viability of AsPC-1, BxPC-3, and Capan-1 cells after exposure to sorafenib and betulinic acid at different drug concentrations (AsPC-1 and Capan-1: 5 µM, BxPC-3: 3 µM) and betulinic acid (6 µM) alone and in combination. (B) The number of AsPC-1, BxPC-3, and Capan-1 cells after treatments with sorafenib (AsPC-1 and Capan-1: 5 µM, BxPC-3: 3 µM) and betulinic acid (6 µM) alone and in combination (n = 4). Data are presented as means ± SD normalized to the untreated control. * p < 0.05, ** p < 0.01 compared with the sorafenib treatment group and betulinic acid treatment group.